Metformin

Rejuvenate Biomed announces positive results from Phase 1b clinical trial with RJx-01 in sarcopenia

Retrieved on: 
Wednesday, October 4, 2023

RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects with disuse-induced muscle atrophy.

Key Points: 
  • RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects with disuse-induced muscle atrophy.
  • In this successful Phase 1b trial, RJx-01 met all primary and secondary endpoints.
  • Rejuvenate Biomed is gearing up to initiate a Phase 2 program focused on RJx-01 in the treatment of sarcopenia in 2024.
  • Subsequently, they were closely monitored during the immobilization phase and for an additional four weeks post-cast removal in the recovery phase.

VALBIOTIS SA: Valbiotis presents the full results of the Phase II/III REVERSE-IT study: impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes

Retrieved on: 
Saturday, September 16, 2023

VALBIOTIS SA: Valbiotis presents the full results of the Phase II/III REVERSE-IT study: impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes

Key Points: 
  • VALBIOTIS SA: Valbiotis presents the full results of the Phase II/III REVERSE-IT study: impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • With REVERSE-IT, TOTUM•63 now has unrivaled proof of efficacy for a non-drug health product against prediabetes and the untreated early stages of type 2 diabetes.
  • We also demonstrated a 40% reduction in the number of new diagnoses of type 2 diabetes among prediabetics.
  • Around 537 million adults (aged 20-79) live with diabetes worldwide, 90% of whom have type 2 diabetes, according to the International Diabetes Federation [1] .

FORM, The Virtual Obesity Medicine Clinic, Launches FORMfit, A New Program Helping Employers Expand Access to High-Quality Obesity Care While Controlling Costs

Retrieved on: 
Tuesday, September 12, 2023

Today, FORM , the virtual obesity medicine clinic, officially launched FORMfitTM, a new program helping employers expand access to high-quality, clinical obesity care while managing costs.

Key Points: 
  • Today, FORM , the virtual obesity medicine clinic, officially launched FORMfitTM, a new program helping employers expand access to high-quality, clinical obesity care while managing costs.
  • FORMfit allows employers to ensure that all employees with obesity have access to best-in-class, specialized clinical care rather than cutting off access due to budgetary constraints.
  • “With nearly half of American adults impacted by obesity and obesity care costs exploding, employers are compelled to find a solution that helps them offer meaningful obesity care and expanded medication access to their employees while managing costs.
  • FORM is a virtual obesity medicine clinic taking an entirely unique approach and pioneering an obesity medicine model that is physician-led and patient-focused.

Long COVID symptoms can improve, but their resolution is slow and imperfect

Retrieved on: 
Sunday, September 3, 2023

Shortness of breath, brain fog, lethargy and tiredness, loss of smell or taste are common features of long COVID, as is the development of new conditions such as diabetes, heart disease, stroke, depression and dementia.

Key Points: 
  • Shortness of breath, brain fog, lethargy and tiredness, loss of smell or taste are common features of long COVID, as is the development of new conditions such as diabetes, heart disease, stroke, depression and dementia.
  • Read more:
    When does COVID become long COVID?
  • This and other recently published studies on long COVID show that while symptoms do resolve in many people, their resolution is slow and imperfect.

What did the study find?

    • The researchers followed 139,000 people with COVID and almost six million uninfected controls for two years, tracking deaths, hospitalisations and 80 long-term impacts of COVID, categorised into ten organ systems.
    • After two years, this “hospitalised” group remained at increased risk of 50 conditions.
    • This included a risk of clots and blood disorders, lung disease, fatigue, gut disorders, muscle and joint disorders and diabetes.

Findings from other recent research were similar

    • The risk of death was concentrated in the first six months after infection.
    • A third, not yet peer-reviewed and smaller cohort study of 341 people with long COVID from Spain, found only 7.6% of them recovered at two years.
    • An Australian (not yet peer-reviewed) study followed 31 people who developed long COVID and 31 matched controls who recovered from COVID for two years.
    • Finally, a recent whole-body positron emission tomography (PET) imaging and biopsy study showed prolonged tissue level immune-activation and viral persistence in the gut for up to a remarkable two years after COVID.

These studies have some limitations

    • It’s important to note the observational studies have some inherent limitations.
    • The US veterans cohort studied by Al-Aly is nearly 90% men, with an average age of 61 years, which is different to groups most at risk of long COVID.

We still don’t have treatments for long COVID

    • In July 2023, the White House established the Office of Long COVID Research and Practice.
    • Two randomised trials are testing whether the antiviral nirmatrelvir-ritonavir (Paxlovid) can treat long COVID are currently recruiting patients.

But it’s still important to prevent COVID (re)infections

    • Taken together, these studies on the longevity of long COVID add substantially to the case to fast-track the development of interventions and therapies to prevent and/or cure the condition.
    • In the meantime, it’s crucially important to prevent (re)infections in the first place to reduce the future burden of long COVID, already estimated to be greater than 65 million people globally.
    • If you suspect you have long COVID, discuss this with your GP, who may refer you to specialised services or multidisciplinary care.

Hua Medicine Announces 2023 Interim Results

Retrieved on: 
Friday, August 25, 2023

Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2023 (the "Reporting Period").

Key Points: 
  • Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2023 (the "Reporting Period").
  • Dr. Li Chen, the founder and CEO of Hua Medicine, said, "the first half of 2023 was a critical stage for Hua Medicine to begin commercialization.
  • The revenue of Hua Medicine for the first half of 2023 was RMB70.3 million, which was an increase of approximately 299.6% comparing to the second half of 2022.
  • This article contains the statements regarding the future expectations, plans and prospects for Hua Medicine and the investigational product.

Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.

Retrieved on: 
Thursday, August 10, 2023

Dr. Reddy’s Saxagliptin and Metformin Hydrochloride Extended-Release Tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30.

Key Points: 
  • Dr. Reddy’s Saxagliptin and Metformin Hydrochloride Extended-Release Tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30.
  • Please click here to see the full prescribing information, including boxed warning: https://drreddys.com/pil/150092247-PIL-Saxagl-Met-HCL-ER-Tab-US_V3_fn.pdf .
  • Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL.
  • (5.1)
    If lactic acidosis is suspected, discontinue saxagliptin and metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting.

Fractyl Health Announces Clinical Update on Revita® Real World Registry in Germany and Launch of Revita+™ Telehealth Program Combining Behavioral Recommendations with Revita Treatment for Type 2 Diabetes

Retrieved on: 
Tuesday, August 1, 2023

Fractyl Health, a metabolic therapeutics company pioneering new approaches to prevent and reverse type 2 diabetes (T2D), today announced clinical updates on the Revita Real World Registry in Germany and the launch of a new telehealth program, called Revita+.

Key Points: 
  • Fractyl Health, a metabolic therapeutics company pioneering new approaches to prevent and reverse type 2 diabetes (T2D), today announced clinical updates on the Revita Real World Registry in Germany and the launch of a new telehealth program, called Revita+.
  • Revita+ is a scalable behavioral modification program created to reduce insulin and glucose excursions.
  • "The initial clinical experiences with Revita DMR in Germany are promising and validate the outcomes observed in previous clinical studies," said Professor Martin.
  • Periodic updates on the Revita Registry and real-world clinical outcomes for patients in Germany undergoing Revita treatment will be shared as the study continues to enroll in more sites.

Dangerous Heat Putting 37 Million People With Diabetes At Greater Risk

Retrieved on: 
Thursday, July 27, 2023

The extreme heat conditions across the US over the past several months can be hazardous for people with diabetes.

Key Points: 
  • The extreme heat conditions across the US over the past several months can be hazardous for people with diabetes.
  • When the temperature rises, so does the risk for diabetes patients to suffer acute myocardial infarction (AMI)1, which is the leading cause of death among people with diabetes.
  • In addition, certain diabetes complications, such as damage to blood vessels and nerves, can affect sweat glands so the body can’t cool as effectively.
  • That can lead to heat exhaustion and heat stroke, which are medical emergencies.2
    For people with diabetes exposed to extreme heat, measuring their blood glucose regularly is vital.

PCORI approves $208 million for research on heart disease, chronic disease, palliative care and a range of conditions impacting people of all ages

Retrieved on: 
Tuesday, July 18, 2023

WASHINGTON, July 18, 2023 /PRNewswire/ -- The Patient-Centered Outcomes Research Institute (PCORI) today announced funding awards totaling $208 million to support 17 new comparative clinical effectiveness research (CER) studies, including four trials of particularly large scale and scope tackling complex questions. All the approved studies aim to fill evidence gaps and enhance health care decision making with a focus on a variety of high-burden concerns.

Key Points: 
  • All the approved studies aim to fill evidence gaps and enhance health care decision making with a focus on a variety of high-burden concerns.
  • Delivery of palliative care led by specialists versus trained general care practitioners to seriously ill hospitalized patients.
  • All funding awards were approved pending a business and programmatic review by PCORI staff and the issuance of formal award contracts.
  • With these latest awards, PCORI has invested more than $4 billion to fund patient-centered CER and other research-related projects.

Capital Rx Launches Rx Reverse in Partnership with Virta Health to Combat Type 2 Diabetes and Obesity

Retrieved on: 
Monday, July 17, 2023

Available to all of Capital Rx's customers, Rx Reverse is a high-touch, provider-led, integrated clinical program designed to help members reverse T2D and fight obesity without costly medications.

Key Points: 
  • Available to all of Capital Rx's customers, Rx Reverse is a high-touch, provider-led, integrated clinical program designed to help members reverse T2D and fight obesity without costly medications.
  • Rx Reverse - a high-touch, provider-led, integrated clinical program - will help members reverse T2D and fight obesity.
  • The launch of Rx Reverse comes as demand for GLP-1 drugs approved for diabetes and weight loss is rising rapidly, and employers and health plan leaders focus on managing the cost of diabetes and obesity.
  • "The rapidly rising utilization and cost of obesity and diabetes drugs is putting extreme pressure on healthcare payers," said Kevin Kumler, President at Virta Health.